Quadrivalent influenza split vaccine (Weiguang Biological Products)

A quadrivalent influenza split vaccine developed by Shenzhen Weiguang Biological Products for the prophylaxis of seasonal influenza. This inactivated vaccine formulation contains antigens from four distinct influenza virus strains, typically including two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). Upon intramuscular administration, the vaccine stimulates the host's immune system to produce strain-specific neutralizing antibodies against the viral hemagglutinin, providing protection against seasonal influenza disease. The vaccine is part of Weiguang's expanding portfolio in the vaccine and blood products sector.

Other names

Quadrivalent influenza split vaccineinfluenza split vaccine (QIV)Weiguang quadrivalent influenza vaccine